Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: Two cases

Critical Care and Resuscitation

Volumn 17, Issue 4, 2015, Pages 280-282

  Venkatesh, Bala ^a   Moore, Geoff ^a   Gill, Denzil ^a   Kelly, Wayne ^b  

^a WESLEY HOSPITAL   (Australia)

^b Mater Private Hospital Brisbane   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; FEMALE; HUMAN; MALE; MIDDLE AGED;

ADULT; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84951914343     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Tahrani AA. SGLT-2 inhibitors as second-line therapy in type 2 diabetes. Lancet Diabetes Endocrinol 2014; 2: 678-9.
2. Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013; 6: 453-67. doi: 10.2147/DMSO.S34416.
3. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015; 100: 2849-52.
4. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Silver Spring, MD: FDA, 2015. http://www. fda.gov/Drugs/DrugSafe ty/ucm446845.htm (accessed Oct 2015).
5. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: 1638-42.
6. Umpierrez GE. Ketosis-prone type 2 diabetes: time to revise the classification of diabetes. Diabetes Care 2006; 29: 2755-7.
7. Goodstein G, Milanesi A, Weinreb J. Ketosis-prone type 2 diabetes in a veteran population. Diabetes Care 2014; 37: e74–5.